Rajkumar Venkatramani
Overview
Explore the profile of Rajkumar Venkatramani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
1099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kelsey A, Alaggio R, Webster F, Bailey K, Bisogno G, Davis J, et al.
Histopathology
. 2025 Feb;
PMID: 40007148
Aims: Rhabdomyosarcoma (RMS) is rare, but it is the most common sarcoma in childhood. The World Health Organisation classifies RMS into four main categories, sharing the same terminology of RMS,...
2.
Zobeck M, Khan J, Venkatramani R, Okcu M, Scheurer M, Lupo P
JCO Precis Oncol
. 2025 Feb;
9:e2400556.
PMID: 39913888
Purpose: Molecular markers increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve...
3.
Mahajan P, May S, Shekar M, Werny D, Patterson B, Chan C, et al.
Pediatr Blood Cancer
. 2025 Jan;
72(4):e31545.
PMID: 39821955
Background: Differentiated thyroid carcinoma (DTC) is the most common pediatric thyroid malignancy, with papillary thyroid carcinoma (PTC) representing 90% of the cases. In 2015, the American Thyroid Association (ATA) developed...
4.
Navai S, Mahajan P, Venkatramani R
Curr Opin Pediatr
. 2024 Dec;
37(1):56-58.
PMID: 39699101
Purpose Of Review: Due to the infrequent nature of rare pediatric cancers, rigorously studied treatment algorithms are usually nonexistent, and experience with a given tumor may be limited at a...
5.
Bisogno G, Minard-Colin V, Haduong J, Zanetti I, Ferrari A, Chisholm J, et al.
Pediatr Blood Cancer
. 2024 Nov;
72(2):e31436.
PMID: 39568171
Background: Prognostic factors are crucial in tailoring treatments for patients with rhabdomyosarcoma (RMS). The European paediatric Soft tissue sarcoma Study Group (EpSSG) and the Children's Oncology Group (COG) employ similar...
6.
Kreimer S, Xue W, Qumseya A, Lautz T, Shenoy A, Hiniker S, et al.
Pediatr Blood Cancer
. 2024 Nov;
72(1):e31421.
PMID: 39502069
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including...
7.
Schneller N, Daw N, Throckmorton W, Mullen E, DeSmith K, Marcarenhas L, et al.
Pediatr Blood Cancer
. 2024 Oct;
72(1):e31347.
PMID: 39394977
Background: The last major North American cooperative group clinical trial for relapsed favorable-histology Wilms tumor (FHWT) was completed in 2002. The outcomes of patients with relapsed Wilms tumor subsequently treated...
8.
Zobeck M, Khan J, Venkatramani R, Okcu M, Scheurer M, Lupo P
medRxiv
. 2024 Sep;
PMID: 39281734
Purpose: Molecular markers, such as fusion genes and and mutations, increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce...
9.
Espinoza A, Shetty P, Jacobson J, Todd H, Harrell K, Trappey A, et al.
Cancer Med
. 2024 Sep;
13(17):e70207.
PMID: 39279240
Introduction: Synovial sarcoma is one of the most common soft tissue sarcomas in children. Guidelines regarding the adequate extent of resection margins and the role of re-resection are lacking. We...
10.
Luo L, Xue W, Qumseya A, Vasquez J, Venkatramani R, Wolden S, et al.
J Clin Oncol
. 2024 Sep;
42(36):4263-4270.
PMID: 39255438
Purpose: Patients with rhabdomyosarcoma with metastatic disease have a poor prognosis despite therapy intensification. The aim of this study was to investigate the efficacy of whole lung irradiation (WLI) in...